ubs analysts: But there's one that would be particularly bad for health stocks, according to Market Watch. The true worst case for biotech and pharma stocks would include any outcome where the Trump administration manages to implement something that is closely based on its current IPI model, analysts wrote, referring to a proposal that would tether what Medicare Part B pays for drugs to an international pricing index or benchmark. There are several possible scenarios for reform, analysts wrote in a 115-page report sent to clients Wednesday. Medicare Part B covers drugs administered to patients in doctors' offices and hospitals. But that would be a tough sell for health companies and their investors, UBS analysts said. Read I'm simply trying not to die,' says one advocate as senior Democrats reluctantly give Medicare for All' more attention Also What Medicare for All' would do to the health-care sector President Donald Trump has complained that other wealthy countries pay far less for the same drugs than the U.S. He's pushed the idea of an international pricing index in order to lower Medicare costs.
(news.financializer.com). As
reported in the news.
Tagged under ubs analysts, page report topics.